Related Experiment Video
Updated: Aug 20, 2026

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
Published on: June 15, 2018
The CRM1 nuclear export receptor controls pathological cardiac gene expression
Brooke C Harrison1, Charles R Roberts, David B Hood
1Myogen Inc., 7575 W. 103rd Ave., Westminister, CO 80021, USA. timothy.mckinsey@myogen.com
Abstract:
Diverse pathological insults trigger a cardiac remodeling process during which myocytes undergo hypertrophy, with consequent decline in cardiac function and eventual heart failure. Multiple transcriptional regulators of pathological cardiac hypertrophy are controlled at the level of subcellular distribution. For example, prohypertrophic transcription factors belonging to the nuclear factor of activated T cells (NFAT) and GATA families are subject to CRM1-dependent nuclear export but are rapidly relocalized to the nucleus in response to cues for hypertrophic growth. Here, we demonstrate that the antihypertrophic chromatin-modifying enzyme histone deacetylase 5 (HDAC5) is shuttled out of the cardiomyocyte nucleus via a CRM1-mediated pathway in response to diverse signals for hypertrophy. CRM1 antagonists block the agonist-mediated nuclear export of HDAC 5 and repress pathological gene expression and associated hypertrophy of cultured cardiomyocytes. Conversely, CRM1 activity is dispensable for nonpathological cardiac gene activation mediated by thyroid hormone and insulin-like growth factor 1, agonists that fail to trigger the nuclear export of HDAC5. These results suggest a selective role for CRM1 in derepression of pathological cardiac genes via its neutralizing effects on antihypertrophic factors such as HDAC5. Pharmacological approaches targeting CRM1-dependent nuclear export in heart muscle may have salutary effects on cardiac function by suppressing maladaptive changes in gene expression evoked by stress signals.
Insights
CRM1 facilitates pathological cardiac hypertrophy by exporting the antihypertrophic enzyme HDAC5 from cardiomyocyte nuclei. Blocking this export with CRM1 antagonists represses pathological gene expression and hypertrophy, suggesting therapeutic potential.
Area of Science:
- Cardiovascular Biology
- Molecular Cardiology
- Epigenetics
Background:
- Pathological cardiac remodeling involves myocyte hypertrophy, leading to heart failure.
- Subcellular distribution of transcriptional regulators controls pathological cardiac hypertrophy.
- Nuclear export of transcription factors like NFAT and GATA is CRM1-dependent.
Purpose of the Study:
- To investigate the role of histone deacetylase 5 (HDAC5) nuclear export in pathological cardiac hypertrophy.
- To determine if CRM1 mediates HDAC5 nuclear export in response to hypertrophic stimuli.
- To evaluate the therapeutic potential of targeting CRM1-dependent nuclear export.
Main Methods:
- Studied the subcellular localization of HDAC5 in cardiomyocytes under hypertrophic conditions.
- Utilized CRM1 antagonists to block nuclear export of HDAC5.
- Assessed the effects of CRM1 inhibition on pathological gene expression and cardiomyocyte hypertrophy.
- Compared CRM1's role in pathological vs. non-pathological cardiac gene activation.
Main Results:
- HDAC5 is exported from the cardiomyocyte nucleus via a CRM1-mediated pathway in response to hypertrophic signals.
- CRM1 antagonists inhibit agonist-induced HDAC5 nuclear export, repressing pathological gene expression and hypertrophy.
- CRM1 activity is not required for non-pathological cardiac gene activation by thyroid hormone and IGF-1.
Conclusions:
- CRM1 selectively promotes pathological cardiac gene expression by enabling the nuclear export of antihypertrophic factors like HDAC5.
- Targeting CRM1-dependent nuclear export offers a potential therapeutic strategy for heart failure by suppressing maladaptive cardiac remodeling.
Related Concept Videos
Nuclear Export
NES are of three types- the canonical 10-residue long leucine-rich signal and other...
Regulation of Nuclear Protein Sorting
Nuclear Export of mRNA
Nuclear Export of mRNA
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Regulation of Expression at Multiple Steps